TCR-a/b+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

Trial Profile

TCR-a/b+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan; Thiotepa
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 05 Aug 2015 Planned End Date changed from 1 Jun 2018 to 1 Nov 2020 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top